isomethyleugenol has been researched along with carboplatin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayo, J; Behrens, C; Bhanu, NV; Coombes, K; Dalvi, MP; Garcia, BA; Gazdar, AF; Girard, L; Heymach, JV; Kalhor, N; Kittler, R; Kollipara, RK; Martinez, ED; Minna, JD; Mino, B; Park, H; Parra, ER; Pataer, A; Rodriguez-Canales, J; Suraokar, M; Swisher, SG; Timmons, BC; Villalobos, P; Wang, L; Wistuba, II; Xie, Y; Yenerall, P; Zhong, R; Zhou, Y | 1 |
1 other study(ies) available for isomethyleugenol and carboplatin
| Article | Year |
|---|---|
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzazepines; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydrazones; Jumonji Domain-Containing Histone Demethylases; Lung Neoplasms; Methylation; Mice; Neoadjuvant Therapy; Pyrimidines; Taxoids; Transcription, Genetic | 2017 |